{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T12:48:11Z","timestamp":1768481291654,"version":"3.49.0"},"posted":{"date-parts":[[2019,5,24]]},"group-title":"Microbiology","reference-count":46,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2019,5,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Viral pathogens causing global disease burdens are often characterised by high rates of evolutionary changes, facilitating escape from therapeutic or immune selective pressure. Extensive viral diversity at baseline can shorten the time to resistance emergence and alter mutational pathways, but the impact of genotypic background on the genetic barrier can be difficult to capture, in particular for antivirals in experimental stages, recently approved or expanded into new settings. We developed an evolutionary-based counting method to quantify the population genetic potential to resistance and assess differences between populations. We demonstrate its applicability to HIV-1 integrase inhibitors, as their increasing use globally contrasts with limited availability of non-B subtype resistant sequences and corresponding knowledge gap on drug resistance. A large sequence dataset encompassing most prevailing subtypes and resistance mutations of first- and second-generation inhibitors were investigated. A varying genetic potential for resistance across HIV-1 subtypes was detected for 15 mutations at 12 positions, with notably 140S in subtype B, while 140C was discarded to vary across subtypes. An additional analysis for HIV-1 reverse transcriptase inhibitors identified a higher potential for 65R in subtype C, on the basis of a differential codon usage not reported before. The evolutionary interpretation of genomic differences for antiviral treatment remains challenging. Our framework advances existing counting methods with an increased sensitivity that identified novel subtype dependencies as well as rejected previous statements. Future applications include novel HIV-1 drug classes as well as other viral pathogens.<\/jats:p>","DOI":"10.1101\/647297","type":"posted-content","created":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T04:55:30Z","timestamp":1558760130000},"source":"Crossref","is-referenced-by-count":2,"title":["An evolutionary-based approach to quantify the genetic barrier to drug resistance in fast-evolving viruses: an application to HIV-1 subtypes and integrase inhibitors"],"prefix":"10.64898","author":[{"given":"Kristof","family":"Theys","sequence":"first","affiliation":[]},{"given":"Pieter","family":"Libin","sequence":"additional","affiliation":[]},{"given":"Kristel Van","family":"Laethem","sequence":"additional","affiliation":[]},{"given":"Ana B","family":"Abecasis","sequence":"additional","affiliation":[]}],"member":"54368","reference":[{"issue":"5","key":"2019052611350300000_647297v1.1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1177\/135965350601100512","article-title":"Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02AG","volume":"11","year":"2006","journal-title":"Antivir. Ther. (Lond.)"},{"issue":"1","key":"2019052611350300000_647297v1.2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/infdis\/jiy436","article-title":"Dolutegravir Resistance and Failure in a Kenyan Patient","volume":"219","year":"2019","journal-title":"J. Infect. Dis"},{"key":"2019052611350300000_647297v1.3","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkp455"},{"key":"2019052611350300000_647297v1.4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1003203"},{"key":"2019052611350300000_647297v1.5","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.6.2792-2794.2003"},{"key":"2019052611350300000_647297v1.6","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir025"},{"key":"2019052611350300000_647297v1.7","doi-asserted-by":"publisher","DOI":"10.2217\/hiv.09.40"},{"key":"2019052611350300000_647297v1.8","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.07133-11"},{"key":"2019052611350300000_647297v1.9","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200308150-00008"},{"key":"2019052611350300000_647297v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61221-0"},{"issue":"17","key":"2019052611350300000_647297v1.11","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1097\/QAD.0000000000001978","article-title":"Two cases of dolutegravir failure with R263K mutation","volume":"32","year":"2018","journal-title":"AIDS"},{"key":"2019052611350300000_647297v1.12","doi-asserted-by":"crossref","unstructured":"C. Charpentier and D. Descamps . Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations. Viruses, 10(1), 01 2018.","DOI":"10.3390\/v10010041"},{"key":"2019052611350300000_647297v1.13","doi-asserted-by":"publisher","DOI":"10.3390\/v7092857"},{"issue":"3","key":"2019052611350300000_647297v1.14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/135965350801300316","article-title":"Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response","volume":"13","year":"2008","journal-title":"Antivir. Ther. (Lond.)"},{"issue":"1","key":"2019052611350300000_647297v1.15","first-page":"vex013","article-title":"Rising prevalence of non-B HIV-1 subtypes in North Carolina and evidence for local onward transmission","volume":"3","year":"2017","journal-title":"Virus Evol"},{"key":"2019052611350300000_647297v1.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2012.08.004"},{"key":"2019052611350300000_647297v1.17","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.meegid.2016.06.047","article-title":"Differences among HIV-1 subtypes in drug resistance against integrase inhibitors","volume":"46","year":"2016","journal-title":"Infect. Genet. Evol"},{"key":"2019052611350300000_647297v1.18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206234"},{"key":"2019052611350300000_647297v1.19","doi-asserted-by":"publisher","DOI":"10.1159\/000360947"},{"key":"2019052611350300000_647297v1.20","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-015-0148-6"},{"key":"2019052611350300000_647297v1.21","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btt162"},{"key":"2019052611350300000_647297v1.22","doi-asserted-by":"crossref","unstructured":"P. Libin , K. Deforche , A. B. Abecasis , and K. Theys . VIRULIGN: fast codon-correct alignment and annotation of viral genomes. Bioinformatics, Oct 2018.","DOI":"10.1101\/409052"},{"issue":"1","key":"2019052611350300000_647297v1.23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/135965350901400108","article-title":"Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02 AG subtypes","volume":"14","year":"2009","journal-title":"Antivir. Ther. (Lond.)"},{"key":"2019052611350300000_647297v1.24","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2013.844649"},{"key":"2019052611350300000_647297v1.25","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01535-07"},{"key":"2019052611350300000_647297v1.26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099390"},{"key":"2019052611350300000_647297v1.27","unstructured":"P. on Antiretroviral Guidelines for Adults and P. Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services, -(-):\u2013, Oct 2018."},{"issue":"4","key":"2019052611350300000_647297v1.28","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annepidem.2017.02.002","article-title":"Increasing HIV-1 subtype diversity in seven states, United States, 2006-2013","volume":"27","year":"2017","journal-title":"Ann Epidemiol"},{"issue":"1","key":"2019052611350300000_647297v1.29","doi-asserted-by":"crossref","first-page":"ofy332","DOI":"10.1093\/ofid\/ofy332","article-title":"Virological Failure in HIV to Triple Therapy With Dolutegravir-Based Firstline Treatment: Rare but Possible","volume":"6","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"2019052611350300000_647297v1.30","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/S2352-3018(18)30317-5","article-title":"Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study","volume":"6","year":"2019","journal-title":"Lancet HIV"},{"key":"2019052611350300000_647297v1.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2013.04.032"},{"key":"2019052611350300000_647297v1.32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/1743-422X-8-149","article-title":"HIV integrase variability and genetic barrier in antiretroviral na\u00efve and experienced patients","volume":"8","year":"2011","journal-title":"Virol. J"},{"key":"2019052611350300000_647297v1.33","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria, 2012. ISBN 3-900051-07-0."},{"key":"2019052611350300000_647297v1.34","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkg100"},{"key":"2019052611350300000_647297v1.35","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-5-74"},{"issue":"4","key":"2019052611350300000_647297v1.36","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2018.8431","article-title":"Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel","volume":"320","year":"2018","journal-title":"JAMA"},{"issue":"2","key":"2019052611350300000_647297v1.37","first-page":"67","article-title":"HIV-1 drug resistance mutations: an updated framework for the second decade of HAART","volume":"10","year":"2008","journal-title":"AIDS Rev"},{"key":"2019052611350300000_647297v1.38","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jcv.2015.07.311","article-title":"Discordant predictions of residual activity could impact dolutegravir prescription upon raltegravir failure","volume":"70","year":"2015","journal-title":"J. Clin. Virol"},{"key":"2019052611350300000_647297v1.39","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1186\/1471-2105-11-409","article-title":"Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscape","volume":"11","year":"2010","journal-title":"BMC Bioinformatics"},{"key":"2019052611350300000_647297v1.40","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01668-12"},{"issue":"7","key":"2019052611350300000_647297v1.41","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3851\/IMP1419","article-title":"Effects of HIV type-1 immune selection on susceptability to integrase inhibitor resistance","volume":"14","year":"2009","journal-title":"Antivir. Ther. (Lond.)"},{"key":"2019052611350300000_647297v1.42","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.8.2993-2998.2004"},{"key":"2019052611350300000_647297v1.43","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000209899.05126.e4"},{"issue":"2","key":"2019052611350300000_647297v1.44","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/135965350200700206","article-title":"A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients","volume":"7","year":"2002","journal-title":"Antivir. Ther. (Lond.)"},{"key":"2019052611350300000_647297v1.45","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2010.0123"},{"key":"2019052611350300000_647297v1.46","doi-asserted-by":"publisher","DOI":"10.1093\/ve\/vex003"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/647297","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T23:12:49Z","timestamp":1768432369000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/647297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,24]]},"references-count":46,"URL":"https:\/\/doi.org\/10.1101\/647297","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1128\/AAC.00539-19","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2019,5,24]]},"subtype":"preprint"}}